A Randomized, Double Masked, Active Controlled, Phase III Study of the Efficacy and Safety of Repeated Doses of Intravitreal VEGF Trap-Eye in Subjects With Diabetic Macular Edema

Trial Profile

A Randomized, Double Masked, Active Controlled, Phase III Study of the Efficacy and Safety of Repeated Doses of Intravitreal VEGF Trap-Eye in Subjects With Diabetic Macular Edema

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2016

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Diabetic macular oedema
  • Focus Registrational; Therapeutic Use
  • Acronyms VIVID-DME
  • Sponsors Bayer; Bayer HealthCare
  • Most Recent Events

    • 09 Jun 2015 Pooled results of sub-analysis of this and VISTA-DME trials (assessing visual outcome) presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
    • 12 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 25 Mar 2015 Two-year results data published in a Regeneron Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top